Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Recent & Breaking News (NEO:CYBN)

Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022

Business Wire April 6, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire April 1, 2022

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Business Wire March 31, 2022

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Business Wire March 29, 2022

Cybin announces additional Adelia milestone achievement

Stockhouse Editorial March 28, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire March 25, 2022

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Business Wire March 24, 2022

Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference

Stockhouse Editorial March 21, 2022

Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

Business Wire March 16, 2022

The StockTalk Cannabis Report: Mar 11, 2022

Dave Jackson March 11, 2022

Cybin leads out in psychedelic-based therapeutics space

Stockhouse Editorial March 8, 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space

GlobeNewswire March 7, 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics

GlobeNewswire March 3, 2022

Cybin to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Business Wire March 2, 2022

Cybin Announces Additional Adelia Milestone Achievement

Business Wire February 18, 2022

Cybin to Participate in Aegis Virtual Conference on February 24, 2022

Business Wire February 15, 2022

Chopra Foundation & NEO Psych Stock Team Up to Advance Psychedelics to Therapeutics

Stockhouse Editorial February 15, 2022

The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental Health

PR Newswire February 15, 2022

NEO Psych Stock Releases Q3 2021 Financials

Stockhouse Editorial February 10, 2022

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Business Wire February 10, 2022